Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cheaper eye drug could save millions in AMD treatment costs

NCT ID NCT03577041

Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at three drugs (bevacizumab, ranibizumab, and aflibercept) used to treat age-related macular degeneration (AMD), a leading cause of blindness in older adults. Researchers will analyze costs and quality of life for 600 patients in France to see which treatment offers the best value. The goal is to help healthcare systems choose the most cost-effective option without compromising patient care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bevacizumab, Ranibizumab, Aflibercept (anti-VEGF drugs given as eye injections)
What this could lead to
If successful, this study could show that a cheaper drug (bevacizumab) works just as well as more expensive ones, potentially saving healthcare systems money while maintaining patient outcomes.
What could go wrong
This is an observational economic model, not a treatment trial. It won't test new drugs or prove which works best for individual patients. Results may not apply outside France.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2020

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients over 50 years of age with a naive neovascular AMD form with a retro-fleeal, unilateral or bilateral location, to be treated with intravitreous injections of Bevacizumab or Ranibizumab or Aflibercept according to the practice of each service

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Naive neovascular AMD form of retro localization foveal, unilateral or bilateral (one eye per patient will be studied), * Patients to be treated with intravitreous injections of Bevacizumab or Ranibizumab or Aflibercept, * Patient using effective contraception if he is of childbearing age * Patient informed and not having made his opposition to the research, * Patient under social security scheme. Exclusion Criteria: * Previous or current treatment of AMD by intravenous injection of anti-VEGF or surgery dating less than 2 months in the studied eye, * Contraindications to the taking of Bevacizumab or Ranibizumab or Aflibercept, * Aphakia in the studied eye, * Fibrosis or retrofoveolar retinal atrophy of the eye studied, * Tearing of the pigment epithelium reaching my macula of the studied eye, * Choroidal neovascularization unrelated to AMD, * Diabetic retinopathy and / or diabetic maculopathy proven, * Glycated hemoglobin greater than 12%, * Known hypersensitivity to pharmaceutical agents used, * Pregnant or lactating women, * Severe active intraocular inflammation, or history autoimmune or idiopathic uveitis, * Active or suspected ocular or periocular infection, * Intraocular pressure\> 25mmHg despite two hypotonizing treatments in eye drops, * Patient under tutorship or curatorship or private public law.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related macular degeneration (AMD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

age-related macular degeneration macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Age-related macular degeneration (AMD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Amiens

    RECRUITING

    Amiens, 80480, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.